The first patient implantation of the investigational Gore Ascending Stent Graft in the ARISE III trial for treating acute type A dissections in high-risk surgical patients  has been announced. The trial will enroll up to 112 patients across multiple US centers, with follow-up assessments over five years to evaluate safety and effectiveness.